DMSO removal reduces stem-cell infusion-related toxicity and allows excellent engraftment of cryopreserved unrelated cord blood and autologous stem cells  by Oliveira, O.M.W. et al.
Our program has transplanted 28 patients to date. The ﬁrst step of
our bloodless transplant protocol employs the use of aggressive
doses of erythropoietin and intravenous iron to a target Hg of 11
g/dL. Apheresis causes anemia and thrombocytopenia necessitat-
ing an average 14 day delay before HDCT allowing the patient’s
hemoglobin and platelet levels to reach 11 g/dL and 100,000
cells/mm3. Standard doses of chemotherapy with BCV (BCNU,
Carboplatin, and VP16) or Melphalan (150-200mg/m2) were ad-
ministered. Routine blood conservation techniques were utilized.
Erythropoietin, intravenous iron, vitamin C, folate, and B complex
were given after transplant to facilitate red blood cell recovery. The
single mortality was attributed to pre-transplant hemoglobin of 7
g/dL at which time our protocol was amended to require a hemo-
globin level of 11g/dL before HDCT. To prevent bleeding, the
patients were prophylactically placed on Interleukin (IL)-11 with
Amicar and vitamin K added when the platelet count fell below
30,000 cells/mcL. Apheresis catheters were removed the day after
reinfusion before thrombocytopenia occurred. No signiﬁcant
bleeding occurred with platelet counts exceeding 5000 cells/mm3.
Hematologic data are outlined in table 1: Individuals unwilling to
accept blood products can undergo HDCT and APBSCT with an
acceptable rate of morbidity and mortality. Blood conservation
techniques may limit the number of transfusions thereby further
decreasing transplant related complications. Public safety concerns
related to transfusion risks, increasing blood shortages and eco-
nomics may require us to establish better transfusion guidelines.
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ONE-YEAR FOLLOWUP: PERIPHERAL CD34 COUNTS TO GUIDE LEU-
KAPHERESIS IN PERIPHERAL HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Grifﬁn, D.L., Donnenberg, A.D., Kiss, J.E., Agha, M.E. University of
Pittsburgh Cancer Institute, Pittsburgh, PA
We previously reported at this meeting a multiparameter model
to predict CD34 collection on the basis of peripheral CD34 counts
obtained on the day of leukapheresis, in conjunction with several
clinical indicators (autologous vs allogeneic, collection number,
gender, length of collection). The model can be expressed: LOG
CD34/kg CONSTANT LOG PB_ABS_CD34 3_HOUR
AUTO  MALE  COL_NO. Where PB_ABS_CD34 is the
absolute peripheral CD34 count in cells/microliter, 3_HOUR in-
dicates length of apheresis collection (0 if 4 hour, 1 if 3 hour),
AUTO indicates transplant type (0 if allo, 1 if auto), MALE
indicates gender (0 if female, 1 if male), and COL_NO indicates
collection number. This model was implemented in 3 phases, with
a learning set (n  60) to create the model, a testing set (n  203)
to validate the model on data not included in the learning set, and
a prospective implementation phase of a reﬁned model based on
the entire data set. The ﬁnal model had coefﬁcients of 5.169, 0.986,
0.151, 0.077, 0.058, and 0.028 (corresponding to the above
equation). This model was capable of predicting actual collections
with an intercept of 0.05, a slope of 1.006, and an R2 of 0.930.
During the prospective implementation phase we attempted to use
this model to determine whether a patient was eligible to initiate
collection. Patients scheduled for a possible ﬁrst collection re-
ported to the outpatient clinic in the morning and had blood drawn
for peripheral CD34 determinations (mean turnaround time  1
hour). The predicted CD34 collection (CD34/kg) was estimated
according to the model and reported to the patient coordinator.
Despite the rapid result reporting, implementation of this algo-
rithm disrupted the clinical schedule and proved infeasible. We
now report a modiﬁed model based on peripheral CD34 counts
obtained the day prior to the day of anticipated initiation of
leukapheresis. The additional parameters included in this model
were disease (multiple myeloma vs other), collection number and
transplant type. The learning data set (n 132) was able to predict
CD34 collection with an R2 of 0.811. Although this was not as
close a ﬁt as the previous model, analysis of sensitivity and speci-
ﬁcity (predicting whether a given collection would yield greater
than 5 105 CD34/kg) revealed a positive predictive value of 84%
and a negative predictive value of 75%. We are now determining
how best to implement this predictive tool in the clinical setting.
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DMSO REMOVAL REDUCES STEM-CELL INFUSION-RELATED TOXICITY
AND ALLOWS EXCELLENT ENGRAFTMENT OF CRYOPRESERVED UN-
RELATED CORD BLOOD AND AUTOLOGOUS STEM CELLS
Oliveira, O.M.W.1, Vieira, M.J.1, Bastos, E.M.S.C.1, Delbuono, E.1,
Ginani, V.C.1, Gordan, L.1, Gouveia, R.V.1, Cecyn, K.Z.2, Carvalho,
M.L.2, Lee, M.L.M.1, Petrilli, A.S.1, Seber, A.1 1. Pediatric Oncology
Institute-GRAACC-UNIFESP, Sao Paulo, SP, Brazil; 2. Hematology
and Hematotherapy-Federal University of Sao Paulo, Sao Paulo, SP,
Brazil
The reinfusion of cryopreserved stem cells (SC) can be associated
with allergies, vomiting, seizures and acute renal failure. All these
reactions may be attributed to the DMSO that is infused with the
stem cells. Since 1999, we have removed the DMSO for all pedi-
atric patients weighting 25 kg, with a DMSO dose 1 g/kg or
with underlying renal or cardiac compromise. Methods: DMSO
was removed according to the New York Blood Center guidelines
for thawing and washing cord blood (CB) units. Brieﬂy, a 1:1
Dextran40 5% albumin solution was slowly added to the SC
product immediately after thawing in a 37°C water bath. The cells
were at ﬁrst washed in 50cc tubes and now, only bags are used. The
bags are centrifuged 400g, 4°C for 20 minutes. The buffy coat is
re-suspended in the same solution and infused over 30 minutes.
The objective of this study is to compare cell yield, viability,
sterility, side effects associated to infusion and engraftment in
children undergoing BMT with unmanipulated grafts or after
DMSO removal. Results: Twenty-six patients with underlying
malignancies were evaluated; 20 received autologous PBSC, 11 of
them with DMSO removal. DMSO was removed from all 6 un-
related CB units. The patients in the groups with and without
DMSO removal had a median age of 5 and 4 years and weighted 18
and 17kg, respectively. In CB transplants the mean mononuclear
cell (MNC) dose was 3  107/kg (2-6). Viability was 80% (53-96).
Cell recovery after thawing was 93% (82-100) and after the DMSO
removal, 96% (73-100). All patients engrafted after a mean of 17
days (11-22). In patients undergoing autologous PBSC transplants
with and without DMSO removal, the mean MNC dose was 7
(2-10) and 9 (3-21) 108/kg, respectively. After thawing, the mean
cell viability was 78% (64-95) and 76% (46-89). Cell recovery was
88% (55-111) and 94% (90-97) and 81% (51-100) after the DMSO
removal. All patients engrafted after a mean of 10 (8-13) vs. 11
(8-15) days, respectively. The patients who receive DMSO-free
grafts did not have any serious adverse reactions associated to the
infusion. Patients for whom the DMSO was not removed had
seizures (1), hypervolemia (2), cardiac arrest (1) and all had some
degree of nausea, vomiting and chills. Conclusions: DMSO re-
moval is safe, reduces the infusion-related toxicity in pediatric
BMT without signiﬁcant cell loss or contamination. Engraftment
is satisfactory in both autologous PBSC and unrelated cord blood
transplants.
Table. Hematologic Data
All
Patients*
(n  28)
Multiple
Myeloma
(n  10)
Lymphoma
(n  16)
Average Hb@ onset
of HDCT (g/dL) 12 13 11.6
Average change in Hb
(g/dL) 5.3 4.7 5.9
Average # Days plts
< 10 (cells/mm3) 4.7 2.5 6.1
Average lowest plts
(cells/mm3) (Nadir
and Range) 5.0 (1-36) 9 (2-36) 5.8 (1-13)
*Includes 2 breast cancer patients.
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